Zambon Group is a multinational pharmaceutical and chemical company founded in 1906, with Headquarter in Bresso (Milan), Italy. It operates directly on three continents - Europe, South America and Asia - with over 2,300 employees in 16 Countries and consolidated sales of € 480 million (+11%, about 80% generated outside Italy). The company has manufacturing plants in different Countries including China for both fine chemicals and finished products, with production lines FDA approved. The Pharmaceuticals Business Unit is divided up by geographical areas, aiming at ensuring the immediate response to the specific needs of each individual market. The main therapeutic areas of interest for Zambon are Respiratory, Woman's care and Pain relief, with focus on mild-moderate diseases. Zambon is developing a portfolio of products ranging from ethical drugs to self-medication products. Zambon's R&D, organized in 3 centres in Italy (Bresso and Vicenza) and Switzerland (Taverne), has developed an expertise in lead and drug optimization (Taverne), Pharmaceutical Technology (Vicenza) and pre-clinical and clinical development (Bresso).

Zambon's Corporate Licensing Department is actively looking for in-licensing of projects/products in the Respiratory, Woman's care, Pain relief and Dermatology. Moreover, Zambon is looking for out-licensing core products in territories where the Company is not present with Affiliates. Zambon's current strategy is to develop a portfolio of products that extends beyond an exclusive focus on ethical drugs, with an integrated product line ranging from classical ethical drugs to OTC and food supplements as well as natural produts playing a role in the target areas. Main medical target currently visited are: GPs, Gynaecologists, ENT, Pediatricians together with Pharmacies, the latter covered by specialized sales lines in key Countries.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.